| Citation: |
LI Tuojian, ZHANG Chao, CHEN Zongtao, LI Xinliang. Methylation status of Septin 9 in peripheral blood and its relationship with colorectal cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(23): 5-8, 13. DOI: 10.7619/jcmp.20222618
|
To detect the methylation status of Septin 9 in the peripheral blood of patients with colorectal cancer (CRC) and analyze the relationship between the methylation of Septin 9 and CRC.
A total of 120 patients with CRC were selected as research objects, and the relationship between the methylation status of Septin 9 in the peripheral blood and the medical materials was analyzed; the serum exosomes isolated from patients with CRC and healthy people were used to treat the CRC cells, and the proliferation and apoptosis of CRC cells were detected.
A total of 1 586 people with health examinations were screened for Septin 9, and 56 of whom were positive for methylation of Septin 9, with a positive rate of 3.5%. Among patients with Septin 9 positive, there were 20 cases (35.7%) with abnormal gastrointestinal status (gastrointestinal inflammation or polyps), while only 5.4% (83/1 530) of patients with Septin 9 negative had abnormal gastrointestinal status, which indicated that the methylation status of Septin 9 in the peripheral blood was closely related to the gastrointestinal status. Among 120 CRC patients, the positive rate of methylation of Septin 9 was 78.4% (73/93); in the comparison of different differentiation degrees, the positive rates of Septin 9 methylation in patients with highly differentiated, moderately differentiated and poorly differentiated CRC were 52.6% (10/19), 79.7% (59/74) and 88.9% (24/27) respectively, and the positive rate of Septin 9 methylation in peripheral blood of patients with poorly differentiated CRC was significantly higher than that of patients with highly differentiated CRC (P=0.006). The sensitivity and specificity of Septin 9 methylation in the peripheral blood were 72.3% and 92.5% respectively. Western blot results showed that the expression of Septin 9 in the exosomes of CRC patients was significantly lower than that in the normal people, while the methylation level of Septin 9 in the exosomes was significantly higher than that in the healthy people (P=0.009, 0.003). The results of this study showed that serum exosomes of CRC patients could significantly promote cell proliferation and inhibit cell apoptosis (P < 0.05 or P < 0.01).
Septin 9 can be used as a marker for early screening of CRC, and the mechanism of Septin 9 may be the proliferation and apoptosis resistance of CRC induced by serum exosomes in patients with CRC.
| [1] |
ZENG H M, ZHENG R S, GUO Y M, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930. doi: 10.1002/ijc.29227
|
| [2] |
KANG Q, JIN P, YANG L, et al. Significance of Septin 9 gene methylation detection of plasma circulation DNA in colorectal cancer screening[J]. Zhonghua Yi Xue Za Zhi, 2014, 94(48): 3839-3841. .
|
| [3] |
SUN G P, MENG J, DUAN H, et al. Diagnostic ssessment of Septin 9 DNA methylation for colorectal cancer using blood detection: a meta-analysis[J]. Pathol Oncol Res, 2019, 25(4): 1525-1534. doi: 10.1007/s12253-018-0559-5
|
| [4] |
LIU T, ZHANG X, DU L T, et al. Exosome transmitted miR-l 28-3p increase chemosensitivity of oxaliplatin-resistant coloretal cancer[J]. Mol Cancer, 2019, 18(1): 43. doi: 10.1186/s12943-019-0981-7
|
| [5] |
谭琪, 宗明, 處珊珊, 等. 联合检测外周血游离Septin 9、SDC2、BCATI基因甲基化在结直肠癌诊断中的意义[J]. 中华检验医学杂志, 2021, 44(3): 204-211. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ201605028.htm
|
| [6] |
YANQING H, CHENG D, LING X. Serum CA72-4 as a bionarker in the diagnosis of colorectal cancer: a meta-analysis[J]. Open Med: Wars, 2018, 13: 164-171. doi: 10.1515/med-2018-0026
|
| [7] |
宋慧琴, 张君娜. Septin 9基因、缺氧诱导因子1与结直肠癌发生发展的相关性[J]. 广州医科大学学报, 2021, 49(1): 14-17. doi: 10.3969/j.issn.2095-9664.2021.01.04
|
| [8] |
YANG J K, YANG J P, TONG J, et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide re sistance in glioma[J]. J Neurooncol, 2017, 131(2): 255-265. doi: 10.1007/s11060-016-2308-5
|
| [9] |
陈培, 邓钦木, 李丹丹. 血浆Septin 9甲基化检测在结直肠癌中的诊断价值[J]. 现代检验医学杂志, 2020, 35(4): 10-13. doi: 10.3969/j.issn.1671-7414.2020.04.003
|
| [10] |
宫媛, 王卫华, 杜海涛, 等. 外周血Septin 9基因甲基化检测在结直肠癌诊断中的研究进展[J]. 临床输血与检验, 2021, 23(2): 263-268. doi: 10.3969/j.issn.1671-2587.2021.02.028
|
| [11] |
张春燕, 于正麟, 王蓓丽, 等. 血浆Septin 9基因甲基化检测性能评价及对结直肠癌患者的筛查价值[J]. 临床检验杂志, 2019, 37(2): 152-155. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJY201902018.htm
|
| [12] |
YAN S S, HAN B, GAO S Y, et al. Exsome-encapsulated micro RNAs as circulating biomarkers for colorectal cancer[J] Oncotarget, 2017, 8(36): 60149-60158. . doi: 10.18632/oncotarget.18557
|
| [13] |
陈越亚, 陈卫昌. 外周血SEPT9基因甲基化检测在结直肠癌中的研究进展[J]. 中国血液流变学杂志, 2021, 31(2): 265-270. doi: 10.3969/j.issn.1009-881X.2021.02.031
|
| [14] |
穆剑强, 高海锋. 外周血Septin9基因甲基化和血清CA199联合检测在结直肠癌筛查中的诊断价值[J]. 检验医学与临床, 2022, 19(4): 526-529. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL202204023.htm
|
| [15] |
RICHARDS K E, ZELENIAK A E, FISHEL M L, et al. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells[J]. Oncogene, 2017, 36(13): 1770-1778.
|
| [16] |
赵媛, 陈四明, 蒋益兰, 等. Septin-9基因甲基化检测对结直肠癌诊断价值的meta分析[J]. 中国医师杂志, 2020, 22(6): 852-856. doi: 10.3760/cma.j.cn431274-20200222-00172
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: